Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma

被引:150
作者
Harousseau, Jean-Luc [1 ]
Moreau, Philippe [2 ]
机构
[1] Rene Gauducheau Canc Ctr, F-44805 Nantes, France
[2] Univ Hosp Hotel Dieu, Nantes, France
关键词
BONE-MARROW-TRANSPLANTATION; HIGH-DOSE THERAPY; INTERGROUPE FRANCOPHONE; RANDOMIZED-TRIAL; STANDARD CHEMOTHERAPY; PLUS DEXAMETHASONE; IMPROVES SURVIVAL; ELDERLY-PATIENTS; MELPHALAN; THALIDOMIDE;
D O I
10.1056/NEJMct0805626
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A previously healthy 59-year-old man presents with persistent pain in his lower back and fatigue. A complete blood count reveals a hemoglobin level of 9.8 g per deciliter. A monoclonal protein (M component) is detected on serum protein electrophoresis and is characterized as an IgG kappa by immunofixation. A radiologic skeletal bone survey shows diffuse lytic bone lesions of the vertebrae and the pelvis. The diagnosis of multiple myeloma is confirmed by bone marrow aspiration, which reveals an infiltrate of 32% plasma cells. The serum calcium and creatinine levels are normal, the albumin level is 3.7 g per deciliter, and the beta(2)-microglobulin level is 2.8 mg per liter. Fluorescence in situ hybridization of bone marrow plasma cells shows deletion of chromosome 13, with no adverse prognostic factors. Considering the patient's relatively young age and the absence of coexisting illnesses, a hematologist recommends induction therapy followed by high-dose therapy with autologous hematopoietic stem-cell transplantation as the initial treatment.
引用
收藏
页码:2645 / 2654
页数:10
相关论文
共 61 条
  • [31] High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial
    Fermand, JP
    Ravaud, P
    Chevret, S
    Divine, M
    Leblond, V
    Belanger, C
    Macro, M
    Pertuiset, E
    Dreyfus, F
    Mariette, X
    Boccacio, C
    Brouet, JC
    [J]. BLOOD, 1998, 92 (09) : 3131 - 3136
  • [32] Harousseau JL, 1999, HAEMATOLOGICA, V84, P548
  • [33] HAROUSSEAU JL, 2008, J CLIN ONCOL, V26, pS455
  • [34] He Y., 2003, COCHRANE DATABASE SY, V2003, DOI [DOI 10.1002/14651858.CD004023, 10.1002/14651858.CD004023]
  • [35] Advances in biology of multiple myeloma: clinical applications
    Hideshima, T
    Bergsagel, PL
    Kuehl, WM
    Anderson, KC
    [J]. BLOOD, 2004, 104 (03) : 607 - 618
  • [36] Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
    Hideshima, Teru
    Mitsiades, Constantine
    Tonon, Giovanni
    Richardson, Paul G.
    Anderson, Kenneth C.
    [J]. NATURE REVIEWS CANCER, 2007, 7 (08) : 585 - 598
  • [37] In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies - Clinical and economic outcomes from the nationwide inpatient sample
    Jones, Jeffrey A.
    Qazilbash, Muzaffar H.
    Shih, Ya-Chen I.
    Cantor, Scoff B.
    Cooksley, Catherine D.
    Elting, Linda S.
    [J]. CANCER, 2008, 112 (05) : 1096 - 1105
  • [38] Kucia M, 2004, J MOL HISTOL, V35, P233
  • [39] Kuehl W Michael, 2005, Hematology Am Soc Hematol Educ Program, P346
  • [40] Drug therapy: Multiple myeloma
    Kyle, RA
    Rajkumar, SV
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (18) : 1860 - 1873